• +44-7451-283651

    contact@mogopharm.com

  • 654 Gulberg St. Abbort Road

    London, 54700. UK

  • Mon - Fri 9:00 - 18:00

    Sat - Sun CLOSED

Our Company

Nullam elementum pulvinar tellus

Transforming cancer immunotherapy with affinity enhanced T-cell receptors

Leading the TCR T-cell therapy space

Mogopharm a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body’s own immune system to find and destroy diseased cells.

Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Mogopharm partners with industry leaders in all areas of its business.

spreads we are focusing on two critical areas:

As COVID-19

OUR Partners